Copper Mountain Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2009



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

XLD - Imaging and Drug Development (C1)


Organizer(s) Lars Farde, Steven M. Larson and Chi-Ming Lee
February 22—26, 2009
Copper Mountain Resort • Copper Mountain, Colorado USA
Abstract Deadline: Oct 21, 2008
Late Abstract Deadline: Nov 21, 2008
Scholarship Deadline: Oct 21, 2008
Early Registration Deadline: Dec 22, 2008

Summary of Meeting:
Positron Emission Tomography (PET) is maturing into a key scientific tool, which is increasingly applied in the scientific community and pharmaceutical industry to study drug distribution, drug-target interactions, and disease processes, especially in CNS and oncology areas. Using specific radiotracers, PET can be performed serially over time in the same live subject to study receptor occupancy and pharmacodynamic response of drug action. These studies can facilitate the selection of drug candidates to advance to clinical trials and guide clinical dose selection. This non-invasive technology also allows longitudinal studies to elucidate the underlying pathophysiology of disease, follow the progression, and monitor the outcome of treatment. The combination of genomic knowledge with PET imaging will provide more specific phenotypes that can help to identify genetic predictors of drug response. The objective of this conference is to bring together a wide range of academic and industrial scientists within the PET molecular imaging community with expertise in imaging systems, analytical tools, and drug discovery/development to address some key issues common to the fields of neurology and oncology. The meeting will provide a forum for the cross-fertilization of experience across these two disciplines, including sharing of knowledge in the development and usage of radiotracers, identifying gaps and opportunities in using PET to facilitate drug development, and discussing innovative solutions to overcome challenges in multi-center trials and biomarker qualification/validation.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 22

15:00—19:30
Registration

Kokopelli's
18:30—19:30
Refreshments

Kokopelli's
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Big Horn B
Steven M. Larson, Memorial Sloan-Kettering Cancer Center, USA
Molecular Imaging in Drug Discovery for Oncology


MONDAY, FEBRUARY 23

07:00—08:00
Breakfast

Kokopelli's
08:00—11:00
Advances in Radiochemistry
Meeting has ended...abstracts no longer viewable online.

Big Horn B
Christer Halldin, Karolinska Institutet, Sweden
Advances in Radiotracer Design and Radiosynthesis of PET Ligands - What are the Remaining Hurdles for Small Molecular Drugs?

Michael R. Zalutsky, Duke University, USA
Advances in Radiotracer Design and Radiosynthesis of Large Biologicals as PET Ligands - Impact and Future Opportunity

Joanna Fowler, Brookhaven National Laboratory, USA
Radiotracer Development and Application in Neuroscience

Victor Pike, National Institutes of Health, USA
PET Radiotracers: Facing the Biological Reality - BBB and Metabolic Enzymes

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

Kokopelli's
11:00
On Own for Lunch

14:30—16:30
Workshop 1: Sharing of PET Radiotracers

Big Horn B
Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

Kokopelli's
17:00—19:00
Advances in Instrumentation
Meeting has ended...abstracts no longer viewable online.

Big Horn B
David W. Townsend, University of Tennessee Medical Center, USA
Development and Impact of PET/CT - Limits and Future Direction

Charles Peck, IBM T.J. Watson Research Center, USA
Performance Gaps beyond the Imaging Instruments: Advances in Data Acquisition and Analysis

Short Talk Chosen from Abstracts

20:00—21:00
Social Hour with Lite Bites

Kokopelli's

TUESDAY, FEBRUARY 24

07:00—08:00
Breakfast

Kokopelli's
08:00—11:00
Molecular Imaging: From Basic to Clinical Research
Meeting has ended...abstracts no longer viewable online.

Big Horn B
Lars Farde, AstraZeneca R&D Södertälje, Sweden
Molecular Imaging in Neuroscience: From Bench to Bedside

Marc Laruelle, GlaxoSmithKline, UK
Early Risk Discharge in CNS Drug Development: The Role of Molecular Imaging

Eric O. Aboagye, Imperial College, UK
Evaluation of PET Radiotracers in Translational Models for Oncology - Limitations and Developments in Animal Models Relevant to Cancer Imaging

Ronald Blasberg, Memorial Sloan-Kettering Cancer Center, USA
Reporter Gene Imaging Studies in Patients: Issues to Address

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

Kokopelli's
11:00—13:00
Poster Setup

Big Horn C
11:00
On Own for Lunch

13:00—22:00
Poster Viewing

Big Horn C
14:30—16:30
Workshop 2: Challenges of Multi-Center Trials Using Molecular Imaging

Big Horn B
Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

Kokopelli's
17:00—19:00
Molecular Imaging of Biological Effects
Meeting has ended...abstracts no longer viewable online.

Big Horn B
John Mann, New York State Psychiatric Institute, USA
PET Imaging in Prediction of Treatment Outcome: Implications for New Drug Development

Ingo K. Mellinghoff, Memorial Sloan-Kettering Cancer Center, USA
Transcriptional Determinants of FDG-PET Retention in Cancer

Tetsuya Suhara, National Institute of Radiological Sciences, Japan
Imaging Biomarker for Proof of Concept

Short Talk Chosen from Abstracts

19:30—22:00
Poster Session 1

Big Horn C
20:00—21:00
Social Hour with Lite Bites

Kokopelli's

WEDNESDAY, FEBRUARY 25

07:00—08:00
Breakfast

Kokopelli's
08:00—11:00
Proof of Biological Activity and Mechanism of Action
Meeting has ended...abstracts no longer viewable online.

Big Horn B
Anthony Shields, Wayne State University, USA
The Use of PET to Image Proliferation in Early Oncology Trials - Status and Use in Drug Development & Patient Management

Julie L. Sutcliffe, University of California, Davis, USA
Highthroughput Screening of Targeted Molecular Imaging Agents

Eric Reiman, Banner Alzheimer's Institute, USA
Positron Emission Tomography in the Evaluation of Alzheimer’s Disease-Slowing and Prevention Therapies

Julie C. Price, University of Pittsburgh, USA
PET Amyloid Imaging

Short Talk(s) Chosen from Abstracts

09:20—09:40
Coffee Break

Kokopelli's
11:00
On Own for Lunch

14:30—16:30
Workshop 3: Challenges for Biomarker Qualification/Validation

Big Horn B
Short Talks Chosen from Abstracts

16:30—17:00
Coffee Available

Kokopelli's
16:30—19:00
Proof of Concept (Biomarker to Surrogate)
Meeting has ended...abstracts no longer viewable online.

Big Horn B
Gary J. Kelloff, National Cancer Institute, National Institutes of Health, USA
Biomarker Qualification and Validation as a Surrogate in Lymphoma and Lung Cancer - Current Progress and Future Challenges for Use in Drug Development

Dean F. Wong, Johns Hopkins Medicine, USA
Neuroreceptor Imaging: Proof of Concept Prebiomarker or Potential Surrogate Marker?

Wayne Drevets, Janssen R&D Pharmaceutical Companies of Johnson & Johnson, USA
Using Molecular Imaging to Identify Phenotypic Differences between Mood Disorder Subtypes

Short Talk Chosen from Abstracts

19:00—20:00
Social Hour with Lite Bites

Kokopelli's
20:00—21:00
Entertainment

Big Horn C

THURSDAY, FEBRUARY 26

 
Departure


*Session Chair †Invited, not yet responded.



We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Cell Press

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676